SAKSHI BAJAAL’s Post

What impact did biosimilars have in 2023? In part 1 of her interview with Pharmacy Times, Fran Gregory, PharmD, MBA VP, Emerging Therapies reflects on key market trends and insights for #biosimilars in 2023 and what to expect in the new year. http://spr.ly/6044RVURY

⚕ Diagnostic Contract Manufacturing Market Set for Rapid Growth ⚕ The global Diagnostic Contract Manufacturing Market is expected to expand significantly, projected to grow from $25.7 billion in 2023 to $57.9 billion by 2031, with a CAGR of 10.78%. 💊 Market Expansion: This growth is driven by the increasing efficiency of outsourcing and advancements in technology across the diagnostic manufacturing sector. 💊 Innovative Applications: The market encompasses a range of devices and services, focusing on areas from infectious diseases to oncology within the In Vitro Diagnostic (IVD) space. 💊 Regional Insights: The Asia Pacific region is predicted to dominate market growth due to robust local industry presence and increasing chronic health issues. #DiagnosticManufacturing #HealthcareInnovation #MarketGrowth #UpendoStaffing #LoveWhatYouDo

⚕ Diagnostic Contract Manufacturing Market Set for Rapid Growth ⚕ The global Diagnostic Contract Manufacturing Market is expected to expand significantly, projected to grow from $25.7 billion in 2023 to $57.9 billion by 2031, with a CAGR of 10.78%. 💊 Market Expansion: This growth is driven by the increasing efficiency of outsourcing and advancements in technology across the diagnostic manufacturing sector. 💊 Innovative Applications: The market encompasses a range of devices and services, focusing on areas from infectious diseases to oncology within the In Vitro Diagnostic (IVD) space. 💊 Regional Insights: The Asia Pacific region is predicted to dominate market growth due to robust local industry presence and increasing chronic health issues. #DiagnosticManufacturing #HealthcareInnovation #MarketGrowth #UpendoStaffing #LoveWhatYouDo

𝗣𝗼𝗶𝗻𝘁-𝗼𝗳-𝗰𝗮𝗿𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 (𝗣𝗢𝗖𝗧) 𝗳𝗼𝗿 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The report offers a comprehensive overview of the Point-of-care Testing (POCT) for Chronic Disease industry chain, encompassing the market status of Hospital and Independent Testing Organizations based on Immunochromatography and Chemiluminescence Technology. It provides a detailed analysis of key enterprises in both developed and developing markets, examining cutting-edge technology, patents, hot applications, and market trends within the Point-of-care Testing (POCT) for Chronic Disease sector. Regionally, North America and Europe are experiencing stable growth due to government initiatives and increased consumer awareness, while Asia-Pacific, led by China, dominates the global market with robust domestic demand, supportive policies, and a strong manufacturing base. The report delivers a holistic understanding of the Point-of-care Testing (POCT) for Chronic Disease market, addressing market dynamics, trends, challenges, and opportunities for stakeholders in the industry. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗣𝗼𝗶𝗻𝘁-𝗼𝗳-𝗰𝗮𝗿𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 (𝗣𝗢𝗖𝗧) 𝗳𝗼𝗿 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/d83UdC29 *𝗕𝘆 𝗧𝘆𝗽𝗲: Based on Immunochromatography, Based on Chemiluminescence Technology, Based on Biosensor, Others *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospital, independent Testing Organization *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Abbott, bioMérieux, Siemens Healthineers, Roche, Danaher Corporation, Sinocare Inc., Assure Tech, Bio-Rad Laboratories, Guangzhou Wondfo Biotech Co., Ltd, Wuhan Easy diagnosis Biomedicine Co.,LTD #POCT #ChronicDiseaseTesting #HealthcareTech #MedicalInnovation #Immunochromatography #ChemiluminescenceTechnology #MarketAnalysis #HealthcareIndustry #POCTMarketTrends #GlobalHealth #DiagnosticTechnology

An Overview of Burosumab Market 2024-2030: Markets & Forecasts, Strategy based, Explore additional https://lnkd.in/eSxbPMiv #marketanalysis #marketresearch #marketresearchreports #businessintelligence

🌟 Exciting News for the Healthcare Industry! 🌟 The #Fibrin #Glue #Market is set to soar with a projected CAGR of 12.02% during the forecast period, reaching nearly US$ 1.61 Bn. by 2029. Our latest report dives deep into this dynamic market, analyzing key trends, opportunities, and challenges. Please connect with our representative, who will ensure you to get a report sample here@ https://lnkd.in/dvSg7z6W 🩺 What is Fibrin Glue? It's a crucial hemostatic agent used in surgeries, derived from human and animal blood products, aiding in wound closure by forming a fibrin clot. 💡 Market Insights: Growing healthcare industry in developing economies offers significant growth prospects. Despite challenges like regulatory requirements, the market remains buoyant, especially due to the surge in minimally invasive procedures. 🔍 Regional Outlook: North America dominates the market, fueled by increased surgical procedures. APAC shows promising growth, especially in countries like China & India, despite concerns about virus contamination. 📊 Our Report Highlights: Comprehensive analysis covering all stakeholders, from market leaders to new entrants. In-depth insights aided by methodologies like PORTER, SVOR, and PESTEL analysis. Clear projections of market dynamics and competitive landscape for informed decision-making. Key Players : • Vivostat A/S • Zimmer Biomet • Johnson & Johnson • Baxter International Inc. • CSL Behring B.V. Get ahead in the healthcare market with our detailed analysis! #HealthcareInnovation #FibrinGlue #MarketInsights #FibrinGlue #MarketAnalysis #IndustryResearch #Healthcare #MedicalDevices #Biotechnology #HealthcareIndustry #MarketTrends #ResearchReport #BusinessAnalysis #HealthcareMarket #MedicalInnovation #MedicalResearch #HealthcareTech #HealthcareTrends #MedTech #BiotechIndustry #HealthcareInsights #MarketInsights #LinkedInMarketing #HealthcareProfessionals #HealthcareManagement #HealthcareBusiness #HealthcareNews #MarketResearch #FibrinSealants #SurgicalSealants #LinkedInPost

𝗙𝗲𝗯𝗿𝗶𝗹𝗲 𝗔𝗻𝘁𝗶𝗴𝗲𝗻 𝗞𝗶𝘁𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dxy9mTuA The report offers an in-depth overview of the Febrile Antigen Kits industry chain, examining the market status across hospitals (High Density Suspension, Standard Suspension) and clinics (High Density Suspension, Standard Suspension). It highlights key enterprises in both developed and developing markets, analyzing cutting-edge technology, patents, hot applications, and market trends. Regionally, the report focuses on key markets such as North America and Europe, which are experiencing steady growth due to government initiatives and rising consumer awareness. Asia-Pacific, especially China, dominates the global market with strong domestic demand, supportive policies, and a robust manufacturing base. The report provides a comprehensive understanding of the Febrile Antigen Kits market, presenting a holistic view of the industry alongside detailed insights into individual components and stakeholders. It analyzes market dynamics, trends, challenges, and opportunities within the industry. *𝗕𝘆 𝗧𝘆𝗽𝗲: High Density Suspension, Standard Suspension *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Clinics, Other *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Fortress Diagnostics, BioTecNika, Atlas Medical, Fondazione Achille Sclavo, Biorex Diagnostics #FebrileAntigenKits #DiagnosticTesting #InfectiousDisease #MedicalDiagnostics #HospitalTesting #ClinicalDiagnostics #HighDensitySuspension #StandardSuspension #HealthcareTechnology #MedicalInnovation #LabTesting #PatientCare #DiseaseDetection #RapidTesting #DiagnosticTools #MarketAnalysis #GlobalHealthcare #MedicalResearch #HealthTech #DiagnosticMarket

Excited to delve into the thriving dynamics of the albumin excipient market! 📈 Our latest report from The Business Research Company unveils compelling insights into its growth trajectory and key trends shaping the industry landscape. With a projected CAGR of 7.6%, the market is poised to reach $4.91 billion in 2024, fueled by factors such as the surge in chronic diseases and innovative drug delivery solutions. 🚀 Key drivers include clinical advancements, global vaccination initiatives, and a growing biologics pipeline, all underscoring the pivotal role of albumin excipients in modern healthcare. Innovative product strategies, strategic acquisitions, and market segmentation further bolster growth prospects, making this an exciting time for stakeholders across the pharmaceutical and biotechnology sectors. From biodegradable properties to regulatory compliance, our report dives deep into the trends shaping the albumin excipient market, providing invaluable insights for industry players worldwide. Explore the full report to unlock a comprehensive understanding of this dynamic market: https://lnkd.in/g8Y3MpiB Let's navigate the future of healthcare together, leveraging innovation and collaboration to drive positive impact and sustainable growth. 💼💡

Those who know me well will understand I have mixed feelings about the complexities involved in market sizing. They require a huge amount of expertise and effort to ensure they do the job that is expected of them. My colleague Jesse C. eloquently itemises the main considerations, the importance of market sizing in general and what it takes to make these projects work. #Healthcare #MarketResearch #GLP1 #MarketSizing

📢 [Point of View] Predicting Opportunity in Emerging Therapies The emergence of novel metabolic markets highlights significant opportunities within previously untapped disease areas. Our latest Point of View (PoV) by Jesse C. explores effective market sizing with GLP-1 drugs as a prime example. Why is market sizing essential? Incorporating epidemiological data, access considerations, real-world patient treatment data and stakeholder perceptions allows a holistic view of the addressable market. The approach presented in our PoV helps pinpoint bottlenecks, key focus areas, and opportunities, equipping manufacturers with the insights needed to make informed decisions in nascent therapeutic areas. Ipsos’ GLP-1 Market Sizing Study will be available in Q4 ‘24 – contact Ramya Logendra to learn more about the study. Discover how to capitalise on these emerging markets – download the article! #Healthcare #MarketResearch #GLP1 #MarketSizing